Occlutech publishes OCCLUFLEX study design manuscript
The study is the first randomized comparison of U.S. approved PFO occluders versus Flex II Occluder, including patients over 60. FDA submission is planned for 2026.
See the latest news and media coverage for Occlutech. We track all announcements, press releases, and industry mentions in real time, all in one place.
Minimally invasive cardiac implant manufacturer
occlutech.comLast updated
In short: Occlutech agreed to a majority stake acquisition by Alkem MedTech for $118 million and launched its ASD Occluder in the U.S. market.
The study is the first randomized comparison of U.S. approved PFO occluders versus Flex II Occluder, including patients over 60. FDA submission is planned for 2026.
He brings over 30 years of MedTech experience, including CEO roles at MEDIRA and prior positions at CryoLife and JOTEC. The appointment strengthens governance for growth.
Procedures occurred at leading cardiac centers post-FDA approval in December 2023. The device shows positive outcomes and low complications. Occlutech partners with B. Braun for U.S. distribution.
The devices treat atrial septal defects minimally invasively. Commercialization begins with B. Braun in the US market.
Indian pharmaceutical company Alkem MedTech plans to acquire a majority stake in Swiss medtech company Occlutech. Alkem intends to buy up to 55% of Occlutech...
BENGALURU, Feb 13 (Reuters) - Alkem Laboratories' medical devices unit will buy up to a 55% stake in...
Alkem Laboratories Limited announced that its wholly owned subsidiary, Alkem Medtech Private Limited, has made a binding offer dated February 13, 2026, to acquire between...
Alkem Laboratories' medical devices unit will buy a stake of up to 55% in Switzerland-based Occlutech Holding for 99.4 million euros ($117.9 million), the pharmaceutical...
Track Occlutech and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Occlutech and other trending companies.